Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study

Inflammatory Bowel Disease

Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

Lancet Gastroenterol Hepatol

Visser E, Reijntjes MA, Heuthorst L, Stellingwerf ME, West R, van Dongen K, Crolla RMPH, van Dieren S, van der Bilt JDW, Bemelman WA, D'Haens GR, Buskens CJ, COSTA Study Group

doi: 10.1016/S2468-1253(25)00291-2

Inflammatory Bowel Disease

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

J Crohns Colitis

Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S

doi: 10.1093/ecco-jcc/jjaf052

Inflammatory Bowel DiseaseFurther Publications

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

United European Gastroenterol J

Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, Mujagic Z, Pierik M, Verleye LMM, Duijvestein M, Bouwknegt DG, Visschedijk MC, Srivastava N, West RL, Oldenburg B, Löwenberg M, van Schaik FDM, Dutch ICC Registry

doi: 10.1002/ueg2.70141

Inflammatory Bowel Disease

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Clin Gastroenterol Hepatol

Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, Amiot A, Vuitton L, Treton X, Caillo L, Pereira B, Fumery M

doi: 10.1016/j.cgh.2025.07.044

Inflammatory Bowel Disease

Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis

Inflamm Bowel Dis

Desai A, Habib H, Khataniar H, Farraye FA, Sehgal P, Barnes EL, Kochhar GS, Hashash JG

doi: 10.1093/ibd/izaf301

Inflammatory Bowel Disease

Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort - an Epi-IBD cohort study

J Crohns Colitis

Wewer MD, Lophaven S, Lakatos PL, Gonczi L, Salupere R, Kievit HAL, Nielsen KR, Midjord J, Domislovic V, Krznarić Ž, Pedersen N, Kjeldsen J, Halfvarson J, Sebastian S, Goldis A, Arebi N, Oksanen P, Neumann A, Andersen V, Katsanos KH, Koukoudis A, Turcan S, Ellul P, Kupcinskas J, Kiudelis G, Fumery M, Kaimakliotis IP, D'Inca R, Lombardini S, Hernandez V, Fernandez A, Langholz E, Munkholm P, Burisch J, Epi-IBD-group

doi: 10.1093/ecco-jcc/jjaf089

Inflammatory Bowel Disease

Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

BMC Gastroenterol

Parra RS, de Sá Brito Fróes R, Magro DO, da Costa Ferreira S, de Mello MK, de Azevedo MFC, Damião AOMC, de Sousa Carlos A, Barros LL, de Miranda MLQ, Vieira A, Sales MPM, Zabot GP, Cassol OS, Tiburcio Alves AJ Jr, Lubini M, Machado MB, Flores C, Teixeira FV, Coy CSR, Zaltman C, Chebli LA, Sassaki LY, Féres O, Chebli JMF

doi: 10.1186/s12876-025-03656-x

Inflammatory Bowel Disease

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Lancet Gastroenterol Hepatol

Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group

doi: 10.1016/S2468-1253(25)00198-0

RECOMMENDED

Inflammatory Bowel Disease

Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU

★ 1 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

J Crohns Colitis

Fuentes-Valenzuela E, Bastón-Rey I, García-Alonso FJ, Elosua A, Zabalza San Martín L, Leo Carnerero E, Garcia de la Filia I, Pedraza Pérez A, Sáiz Chumillas RM, Pascual Oliver A, Muñoz Villafranca C, Moreno V, Suárez Ferrer C, Molina G, Ferreiro-Iglesias R, Vega Villaamil P, Gardeazábal Mateos D, Segarra-Ortega JX, Garrido Marín A, Doallo AI, Alonso-Galán H, Brunet-Mas E, Jimenez García N, López Romero-Salazar F, Velayos B, Carballo-Folgoso L, Pérez Santamaría C, Mata Román L, Núñez Ortiz A, Barrio J, Barreiro-de Acosta M, Gutiérrez-Casbas A, Young GETECCU group

doi: 10.1093/ecco-jcc/jjaf058

Related content

Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis

Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort - an Epi-IBD cohort study

Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU